alexa Cardiomyopathy | Argentina| PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.


  • Cardiomyopathy

    Patho physiology: Cardiomyopathy refers to diseases of the heart muscle. These diseases have many causes, signs and symptoms, and treatments.In cardiomyopathy, the heart muscle becomes enlarged, thick, or rigid. In rare cases, the muscle tissue in the heart is replaced with scar tissue.As cardiomyopathy worsens, the heart becomes weaker. It's less able to pump blood through the body and maintain a normal electrical rhythm. This can lead to heart failure or irregular heartbeats called arrhythmias. In turn, heart failure can cause fluid to build up in the lungs, ankles, feet, legs, or abdomen.The weakening of the heart also can cause other complications, such as heart valve problems.

  • Cardiomyopathy

    Treatment: People who have cardiomyopathy but no signs or symptoms may not need treatment. Sometimes, dilated cardiomyopathy that comes on suddenly may go away on its own. For other people who have cardiomyopathy, treatment is needed. Treatment depends on the type of cardiomyopathy you have, the severity of your symptoms and complications, and your age and overall health. Treatments may include: Heart-healthy lifestyle changes, Medicines, Nonsurgical procedure, Surgery and implanted devices. The main goals of treating cardiomyopathy include: • Controlling signs and symptoms so that you can live as normally as possible • Managing any conditions that cause or contribute to the disease • Reducing complications and the risk of sudden cardiac arrest • Stopping the disease from getting worse

  • Cardiomyopathy

    Research: Prevalence and Disease Outcome: because recognition of inherited disease is often limited by practice patterns which are in turn heavily influenced by the urgent demands of caring for sick patients, an important proportion of inherited disease is misdiagnosed. As an example, we discovered that nearly 25% of patients undergoing heart transplant for end stage cardiomyopathy have inherited disease, whereas current recognition of inherited disease in this population is limited to 4% of patients. This research was presented at the International Society of Heart and Lung Transplant in Prague (2012).

  • Cardiomyopathy

    Statistics: 7.34 deaths/1,000 population (2014 est.) A dynamic cardiomyoplasty procedure was performed in 15 patients with a mean age of 59.2 ± 6.4 years old. Despite the medical treatment with inhibitors of the converted enzyme or vasodilators, all of these patients required 2.2 ± 0.7 hospitalizations/patient/year owing to congestive heart failure in the year before dynamic cardiornioplasty was applied. In 8 patients the etiology of the cardiomyopathy was idiopathic, isc hern ic-ne erotic in 6 and Chagas' disease in the other. Hemodynamic studies were done preoperatively in all patients and every six months postop-eratively. Twelve patients had a follow-up for two years. The following values related to two-years evaluation improved significantly in comparison with baseline: functional class (1.7 ± 0.6 versus 3.06 ± 0.2); radiomiclide left ventricular ejection fraction (29.7 ± 5% versus 23.6 ± 3%); fractional shortening (20.6 ± 5% versus 15.6 ± 4%). Walking test values increased from 332 ± 127 meters to 421 ± 102 meters. Left ventricular diastolic diameter remained unchanged (72.7 ± 7 mm versus 72.3 ± 8 mm). Improvement was observed in functional capacity and left ventricle systolic function parameters two years after cardiomyoplasty was applied.

Speaker PPTs

High Impact List of Articles

Conference Proceedings